# Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)

> **NCT00983138** · PHASE2 · COMPLETED · sponsor: **medac GmbH** · enrollment: 12 (estimated)

## Conditions studied

- Acute Lymphoid Leukemia

## Interventions

- **DRUG:** recombinant asparaginase

## Key facts

- **NCT ID:** NCT00983138
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2011-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983138, "Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00983138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*